Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet all of the following criteria for enrollment in this study:~1. Parent or legal guardian(s) must provide written informed consent prior to any study procedures being performed and must be willing to comply with all study-required procedures. Where appropriate and required by local regulations, patient assent should also be provided prior to any study procedures being performed.~2. Documented diagnosis of HPP as indicated by:~   1. Total serum alkaline phosphatase (ALP) below the lower limit of normal for age NOTE: Historical values for ALP may be used to determine patient eligibility.~  2. Plasma pyridoxal-5'-phosphate (PLP) above the upper limit of normal (unless patient is receiving pyridoxine for seizures) NOTE: Historical values for PLP may be used to determine patient eligibility.~  3. Radiographic evidence of HPP at screening, characterized by:~      * Flared and frayed metaphyses, and~     * Severe, generalized osteopenia, and~     * Widened growth plates, and~     * Areas of radiolucency or sclerosis~  4. Two or more of the following HPP-related findings:~      * History or presence of: i) Nontraumatic post-natal fracture or ii) Delayed fracture healing~     * Nephrocalcinosis or history of elevated serum calcium~     * Functional craniosynostosis~     * Respiratory compromise or rachitic chest deformity~     * Vitamin B6-responsive seizures~     * Failure to thrive~3. Onset of symptoms prior to 6 months of age~4. Chronological age or adjusted age for premature infants born ≤ 37 weeks gestation of ≤ 5 years~5. Otherwise medically stable in the opinion of the Investigator and/or Sponsor~Exclusion criteria:~Patients will be excluded from enrollment in this study if they meet any of the following exclusion criteria:~1. Clinically significant disease that precludes study participation, in the opinion of the Investigator and/or Sponsor~2. Serum calcium or phosphate levels below the normal range~3. Current evidence of treatable form of rickets~4. Prior treatment with bisphosphonates~5. Treatment with an investigational drug within 1 month prior to the start of asfotase alfa treatment~6. Current enrollment in any other study involving an investigational new drug, device or treatment for HPP (e.g., bone marrow transplantation)~7. Intolerance to the investigational product (IP) or any of its excipients~8. Previous participation in the same study~9. Family relative of the Investigator

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Asfotase alfa (Type: EXPERIMENTAL): A total of 6 mg/kg/week of asfotase alfa administered by SC injection (either 1 mg/kg asfotase alfa 6 times per week, or 2 mg/kg asfotase alfa 3 times per week)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete